13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-005947-22-IT
(EUCTR)
17/11/202112/10/2021Effect of siponimod on progressive multiple sclerosisEffect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis - Effect of siponimod on progressive multiple sclerosis Active progressive MS course after an initial relapse clinical course
MedDRA version: 21.1;Level: PT;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Siponimod 2 mg
Product Code: [Siponimod]
INN or Proposed INN: Siponimod
Product Name: Siponimod 0,25 mg
Product Code: [Siponimod]
INN or Proposed INN: Siponimod
Product Name: Siponimod 1 mg
Product Code: [Siponimod]
INN or Proposed INN: Siponimod
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 4Italy